Adaptimmune Therapeutics Plc has appointed a former Novartis executive as chief commercial officer to oversee its first US regulatory submission for a cancer drug. Dr Cintia Piccina joins on 31 January from 2seventy bio Inc, a US company with investigational cell therapies for cancer. Prior to this, she was head of commercial oncology at bluebird bio Inc. and led the launch of Abecma for multiple myeloma.
Dr Piccina holds a doctorate in pharmacy and biochemistry from the University of Sao Paulo in Brazil as well as a master of business administration.
Adaptimmune Therapeutics Plc announced the appointment on 26 January 2022.
Copyright 2022 Evernow Publishing Ltd